TDM-105795 phase 2 results are in!
Research/Science 2/6/2024

At a glance

In this treatment experience post, the primary subjects mentioned are

💧 TDM-105795 (topical) 0.02% and 0.0025% 1x daily 4 months

💧 Minoxidil (topical)

💊 Finasteride (oral)

💧 RU58841 (topical)

the tone is 😀 positive with promising hair growth results.

Other terms

placebo hair follicle stem cells anagen telogen RU pyrilutamide androgens HFSCs stimulant anti androgen systemic absorption molecular weight FPHL ethanol PG Rogaine Propecia propylene glycol

TDM-105795 showed promising hair growth results, with higher efficacy than placebo and minimal side effects. It activates dormant hair follicle stem cells and may maintain gains without immediate loss, unlike minoxidil.

View this post in the Community →

Similar Community Posts Join

5 / 30 results

community Why TDM-105795 is not much talked about like GT20029 and HMI 115 despite having far better Trial results?

undauntedcurious in Research/Science 33 upvotes 8 months ago

TDM-105795 showed better efficacy and safety in trials for hair loss, with a higher hair count improvement compared to GT20029 and HMI 115, but it's not as widely discussed. The user is questioning why this is the case.

community Is there any new drug that looks promising ?

user878767901 in Research/Science 25 upvotes 11 months ago

The conversation discusses GT20029, a drug in Phase II trials that targets androgen receptors with minimal systemic effects, and TDM-105795, a growth stimulant with a different mechanism than minoxidil that may revive papilla stem cells. Both are potential new treatments for hair loss.

community Target Area Hair Count (TAHC) increase comparasion of all future treatments in clinical trial phases

hzah1 in Research/Science 35 upvotes 9 months ago

Finasteride, Minoxidil, Bioneer CosmeRNA, Technoderma, Kintor, Hope, Breezula, and Follicum treatments showed increases in hair count, with Technoderma showing the highest increase at 24.3 hairs/cm². Amplifica has not yet published results.

community GT20029 China Phase II Trial For AGA Reached Primary Endpoint

Synizs in Research/Science 134 upvotes 9 months ago

The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.

community (Serious) Updates and discussion, new treatments in development

First-Element in Treatment 7 upvotes 7 months ago

Finasteride, minoxidil, and derma rolling are currently the best treatments for hair loss. New treatments like TDM-105795, GT20029, PP405, HMI 115, Tsuji, Scube 3, RU, JW0061, Topilutamide, and verteporfin show promise but have uncertain timelines.